A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of BR1010 in Essential Hypertension Patients Who do Not Adequately Respond to Fimasartan/Amlodipine Combination
Latest Information Update: 03 Aug 2021
At a glance
- Drugs Amlodipine/fimasartan/hydrochlorothiazide (Primary) ; Amlodipine/fimasartan
- Indications Essential hypertension
- Focus Registrational; Therapeutic Use
- Acronyms FINAL
- Sponsors Boryung Pharmaceutical
Most Recent Events
- 28 Jul 2021 Status changed from recruiting to completed.
- 09 Sep 2019 Status changed from not yet recruiting to recruiting.
- 21 Jun 2019 New trial record